Cargando…

Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive

Patients with BRAF V600 (BRAF) mutated metastatic melanoma are eligible for therapy with both immune checkpoint inhibitors and targeted therapies, making treatment choice a complex decision. The present study aimed to describe patterns of treatment with immunotherapy and targeted therapy and BRAF te...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghate, Sameer, Ionescu-Ittu, Raluca, Burne, Rebecca, Ndife, Briana, Laliberté, François, Nakasato, Antonio, Duh, Mei Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	ORIGINAL ARTICLES: Epidemiology of melanoma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494034/ https://www.ncbi.nlm.nih.gov/pubmed/30247203 http://dx.doi.org/10.1097/CMR.0000000000000504

Ejemplares similares

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma
por: Tarhini, Ahmad, et al.
Publicado: (2018)

Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
por: Luke, Jason J.
Publicado: (2019)

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2020)

Multidisciplinary Care of BRAF‐Mutant Stage III Melanoma: A Physicians Perspective Review
por: Cornelius, Lynn A., et al.
Publicado: (2021)

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
por: Thompson, John F., et al.
Publicado: (2014)

Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma
por: Di Guardo, Lorenza, et al.
Publicado: (2021)

Improved Perioperative Seroma and Complication Rates Following the Application of a 2-Layer Negative Pressure Wound Therapy System After Inguinal Lymphadenectomy for Metastatic Cutaneous Melanoma
por: Moncrieff, Marc D., et al.
Publicado: (2020)

Development of encorafenib for BRAF-mutated advanced melanoma
por: Koelblinger, Peter, et al.
Publicado: (2018)

Sorting Through the Heterogeneity of Recurrent Melanoma
por: Jacobs, Lisa K., et al.
Publicado: (2008)

Survival and the Sentinel Lymph Node in Melanoma
por: Faries, Mark
Publicado: (2009)

Cutaneous Melanoma and Sentinel Lymph Node Biopsy
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Isolated Tumor Cells and Long-Term Prognosis of Patients with Melanoma
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?
por: Sondak, Vernon K., et al.
Publicado: (2009)

Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma
por: El Sharouni, Mary-Ann, et al.
Publicado: (2019)

Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2016)

The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
por: Wei, Xiaoting, et al.
Publicado: (2020)

Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site
por: Gos, Aleksandra, et al.
Publicado: (2014)

Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
por: Wevers, K. P., et al.
Publicado: (2012)

Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients
por: Park, Tristen S., et al.
Publicado: (2017)

COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States
por: Davis, Catherine H., et al.
Publicado: (2021)

Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site
por: Prens, Sebastiaan P., et al.
Publicado: (2011)

S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients
por: Kruijff, S., et al.
Publicado: (2009)

Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
por: Lawless, Anna K., et al.
Publicado: (2022)

Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm)
por: Holmberg, Carl-Jacob, et al.
Publicado: (2023)

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy
por: Bloemendal, Martine, et al.
Publicado: (2019)

Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-Analysis
por: Ahmadi, Omid, et al.
Publicado: (2021)

The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma
por: Dieng, Mbathio, et al.
Publicado: (2022)

Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients
por: Hussain, Zahra, et al.
Publicado: (2022)

Detection of Melanoma Nodal Metastases; Differences in Detection Between Elderly and Younger Patients Do Not Affect Survival
por: Kruijff, S., et al.
Publicado: (2010)

Potential Cost-Effectiveness of US-Guided FNAC in Melanoma Patients as a Primary Procedure and in Follow-Up
por: van Akkooi, Alexander C. J., et al.
Publicado: (2009)

Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma
por: Belgrano, Valerio, et al.
Publicado: (2019)

Effectiveness of SPECT/CT Imaging for Sentinel Node Biopsy Staging of Primary Cutaneous Melanoma and Patient Outcomes
por: Moncrieff, Marc, et al.
Publicado: (2021)

Comments on Post-Publication Discussion of “Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma”
por: Cook, Robert W., et al.
Publicado: (2022)

Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma
por: Kruijff, S., et al.
Publicado: (2011)

20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters
por: Deroose, Jan P., et al.
Publicado: (2011)

Individualized Surgery: Gamma-Probe-Guided Lymphadenectomy in Patients with Clinically Enlarged Lymph Node Metastases from Melanomas
por: Kretschmer, Lutz, et al.
Publicado: (2013)

Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study
por: Wade, Ryckie G., et al.
Publicado: (2018)

A Clinical Decision Tool to Calculate Pretest Probability of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
por: Tripathi, Raghav, et al.
Publicado: (2023)

Therapeutic Surgical Management of Palpable Melanoma Groin Metastases: Superficial or Combined Superficial and Deep Groin Lymph Node Dissection
por: van der Ploeg, A. P. T., et al.
Publicado: (2011)

Lymphatic Drainage Patterns from Melanomas on the Shoulder or Upper Trunk to Cervical Lymph Nodes and Implications for the Extent of Neck Dissection
por: Veenstra, Hidde J., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ja3jr9mdlfh61t1hlpqgk58qqg